4 results about "Animal cell line" patented technology

The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.

This invention relates to synthetic biology, gene and cell therapy, and particularly to a gene translation system regulated by non-natural amino acids and its applications. This gene translation system precisely regulates gene expression initiation using non-natural amino acids. The invention also provides eukaryotic expression vectors, mammalian cell lines, microcapsules, vacuum fiber tubes, and non-natural amino acid cookies containing the aforementioned gene translation system. Furthermore, this invention discloses that the multifunctional platform can precisely regulate insulin expression and release for diabetes treatment; this gene expression regulation platform can be used to construct complex biological computer-controlled systems. This invention provides a powerful new gene expression regulation tool for gene therapy and cell therapy.

The application discloses a method for continuous editing of multi-site chromosomes in eukaryotic cells. The application provides a method for integrating the genome of eukaryotic cells, comprising: using a knock-in site-specific recombination site (such as noxM) in the genome of eukaryotic cells, realizing integration of a large fragment circular DNA molecule at a specific site of the genome under the action of a knock-in site-specific recombinase (such as Nigri), and simultaneously using an adjacent knock-out site-specific recombination site (such as loxP or a mutant thereof), rearranging the related sites under the action of a knock-out site-specific recombinase (such as Cre), so as to realize continuity of integration. The novel editing platform of high-efficiency site-specific recombination provided by the application can realize directional, continuous and multi-site integration of a large fragment DNA in eukaryotic cells, and the application has important application prospects in the field of biological technologies including plant breeding, animal cell line development, fungus engineering and the like.

The present invention relates to a method comprising the steps of a) contacting ex vivo a cell from a mammalian cell line capable of secreting cytokines in a liquid medium with a set of antibodies from a blood sample from a mammalian subject which is known to be healthy or to suffer from a first disease; b) detecting the level of at least one cytokine present in the liquid medium following step a); c) contacting ex vivo a cell from the mammalian cell line capable of secreting cytokines with a set of antibodies from a blood sample from a mammalian reference subject which is known to be healthy or to suffer from a second disease in a liquid medium; d) detecting the level of the at least one cytokine present in the liquid medium following step c); e) determining a cytokine signature by determining the difference between the level of the at least one cytokine determined in step b) and the level of the at least one cytokine determined in step d), wherein the method is a method for aiding in detecting or diagnosing a disease, a method for aiding in distinguishing between a first disease and a second disease, or a method for aiding in diagnosing whether a mammalian subject is likely to suffer from a disease.